Computer Sciences Corp. [CSC] says its DynPort Vaccine Company (DVC) LLC has been notified by the Defense Department that all future funding for advanced development of plague vaccine will be allocated to the company’s existing contract with the Joint Project Manager Chemical, Biological and Medical Systems’ Joint Vaccine Acquisition Program, Joint Product Management Office. DVC will continue development of a recombinant plague vaccine candidate, rR1V, up to and including possible licensure by the Food and Drug Administration. The vaccine candidate is currently in Phase 2 clinical trials.
free preview